Safety and Efficacy of OBX-115 in Advanced Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06060613 |
Recruitment Status :
Recruiting
First Posted : September 29, 2023
Last Update Posted : April 11, 2024
|
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | September 22, 2023 | ||||
First Posted Date ICMJE | September 29, 2023 | ||||
Last Update Posted Date | April 11, 2024 | ||||
Actual Study Start Date ICMJE | October 25, 2023 | ||||
Estimated Primary Completion Date | October 30, 2025 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE |
|
||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Safety and Efficacy of OBX-115 in Advanced Solid Tumors | ||||
Official Title ICMJE | A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors | ||||
Brief Summary | This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors. | ||||
Detailed Description | Primary Objective (Phase 1): • Assess the safety and tolerability of OBX-115 regimen Primary Objective (Phase 2): • Evaluate preliminary efficacy of OBX-115 regimen as measured by the investigator using objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Secondary (Phase 1): • Assess preliminary efficacy of OBX-115 regimen by evaluating ORR Secondary (Phase 2): • Evaluate safety and tolerability of OBX 115 based on the collected AE data Secondary (both Phase 1 and Phase 2):
|
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 Phase 2 |
||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: Single group assignment Masking: None (Open Label)Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE | Biological: OBX-115
A tumor sample is obtained from each participant for autologous OBX-115 manufacture. After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by a short course of acetazolamide. |
||||
Study Arms ICMJE | Experimental: Participants with advanced solid tumors
Participants will receive conditioning therapy prior to administration of OBX-115 regimen.
Intervention: Biological: OBX-115
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE |
52 | ||||
Original Estimated Enrollment ICMJE |
32 | ||||
Estimated Study Completion Date ICMJE | October 30, 2027 | ||||
Estimated Primary Completion Date | October 30, 2025 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT06060613 | ||||
Other Study ID Numbers ICMJE | OBX115-23-01 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | Obsidian Therapeutics, Inc. | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Obsidian Therapeutics, Inc. | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE | Not Provided | ||||
PRS Account | Obsidian Therapeutics, Inc. | ||||
Verification Date | April 2024 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |